Kim DD, Baron AD: Effectiveness of pro-gressive dose-escalation of exenatide (ex-endin-4) in reducing dose-limiting side-effects in subjects with type 2 diabetes.Diabetes Metab Res Rev . In press 15. Groop LC: Sulfonylureas in NIDDM. Di- abetes Care 15:737–754, 199216. Groop LC, Barzilai N, Ratheiser K, Luzi L, Wahlin-Boll E, Melander A, DeFronzo RA:Dose-dependent effects of glyburide on in-sulin secretion and glucose uptake in hu-mans. Diabetes Care 14:724–727, 1991 17. Wahlin-Boll E, Sartore G, Melander A, Schersten B: Impaired effect of sulfonyl-urea following increased dosage. Eur J Clin Pharmacol 22:21–25, 1982 18. Neter J, Wasserman W, Kutner MH: Ap- plied Linear Statistical Models: Regression,Analysis of Variance, and Experimental De-signs. 3rd ed. Homewood, IL, Irwin, 1990 19. Milliken GA, Johnson DE: Analyses of Messy Data: Vol I: Designed Experiments.New York, Van Nostrand Reinhold, 1984 20. Hayter AJ: The maximum familywise er-